Jove
Visualize
Contact Us

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.

Cancer medicine·2026
Same author

COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort study.

European journal of cancer (Oxford, England : 1990)·2026
Same author

PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients.

Frontiers in immunology·2026
Same author

Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828].

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

<i>ROS1</i>-positive non-small cell lung cancer: from genomics to treatment decisions.

Frontiers in oncology·2026
Same author

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients.

Advances in therapy·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 11, 2026

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis
07:52

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis

Published on: December 21, 2014

[Angiogenesis and lung cancer].

Maurice Pérol1, Dominique Arpin

  • 1Service de Pneumologie, Hôpital de la Croix-Rousse, 69317 Lyon Cedex 04. maurice.perol@chu-lyon.fr

Bulletin Du Cancer
|September 13, 2007
PubMed
Summary

Targeting tumor vascular development through anti-angiogenesis is a key lung cancer treatment strategy. Inhibiting the vascular endothelial growth factor (VEGF) pathway shows survival benefits, especially in non-small cell lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Context:

  • Angiogenesis is crucial for tumor growth and metastasis in lung cancer.
  • Vascular Endothelial Growth Factor (VEGF) pathway is a primary target for anti-angiogenic therapies.
  • Current research focuses on inhibiting VEGF-receptor binding or downstream signaling.

Purpose:

  • To evaluate the efficacy of anti-angiogenic agents targeting the VEGF pathway in lung cancer treatment.
  • To explore the role of bevacizumab in combination with chemotherapy for non-small cell lung cancer.
  • To assess the potential of novel small molecules inhibiting VEGF-receptors.

Summary:

  • Inhibiting tumor vascular development via anti-angiogenesis is a vital lung cancer treatment strategy.
  • Bevacizumab, targeting the VEGF pathway, combined with chemotherapy, offers survival advantages in non-small cell lung cancer.

More Related Videos

Angiogenesis in the Ischemic Rat Lung
07:36

Angiogenesis in the Ischemic Rat Lung

Published on: February 8, 2013

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Experiment Videos

Last Updated: Jul 11, 2026

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis
07:52

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis

Published on: December 21, 2014

Angiogenesis in the Ischemic Rat Lung
07:36

Angiogenesis in the Ischemic Rat Lung

Published on: February 8, 2013

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

  • Ongoing development of small molecule inhibitors targeting VEGF-receptors shows promise, likely in combination therapies.

    • Impact:

    • Demonstrates proof-of-concept for anti-angiogenesis in lung cancer therapy.
    • Highlights the need for careful patient selection due to potential toxicities like pulmonary hemorrhage.
    • Emphasizes the importance of understanding angiogenesis and surrogate markers for improved therapeutic design.